JP2023513312A5 - - Google Patents

Info

Publication number
JP2023513312A5
JP2023513312A5 JP2022548653A JP2022548653A JP2023513312A5 JP 2023513312 A5 JP2023513312 A5 JP 2023513312A5 JP 2022548653 A JP2022548653 A JP 2022548653A JP 2022548653 A JP2022548653 A JP 2022548653A JP 2023513312 A5 JP2023513312 A5 JP 2023513312A5
Authority
JP
Japan
Prior art keywords
aqueous composition
composition according
calcium
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513312A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/017880 external-priority patent/WO2021163504A1/en
Publication of JP2023513312A publication Critical patent/JP2023513312A/ja
Publication of JP2023513312A5 publication Critical patent/JP2023513312A5/ja
Pending legal-status Critical Current

Links

JP2022548653A 2020-02-13 2021-02-12 ヒト抗tslp抗体の製剤及び炎症性疾患を治療する方法 Pending JP2023513312A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062976007P 2020-02-13 2020-02-13
US62/976,007 2020-02-13
US202163148105P 2021-02-10 2021-02-10
US63/148,105 2021-02-10
PCT/US2021/017880 WO2021163504A1 (en) 2020-02-13 2021-02-12 Formulations of human anti-tslp antibodies and methods of treating inflammatory disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026015698A Division JP2026074118A (ja) 2020-02-13 2026-02-02 ヒト抗tslp抗体の製剤及び炎症性疾患を治療する方法

Publications (2)

Publication Number Publication Date
JP2023513312A JP2023513312A (ja) 2023-03-30
JP2023513312A5 true JP2023513312A5 (https=) 2024-02-20

Family

ID=74858823

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548653A Pending JP2023513312A (ja) 2020-02-13 2021-02-12 ヒト抗tslp抗体の製剤及び炎症性疾患を治療する方法

Country Status (18)

Country Link
US (1) US20230078678A1 (https=)
EP (1) EP4103235A1 (https=)
JP (1) JP2023513312A (https=)
KR (1) KR20220140772A (https=)
CN (1) CN115279404A (https=)
AU (1) AU2021219839A1 (https=)
BR (1) BR112022016010A2 (https=)
CA (1) CA3166964A1 (https=)
CL (1) CL2022002193A1 (https=)
CO (1) CO2022012868A2 (https=)
CR (1) CR20220457A (https=)
IL (1) IL295042A (https=)
JO (1) JOP20220183A1 (https=)
MX (1) MX2022010012A (https=)
PE (1) PE20230112A1 (https=)
PH (1) PH12022552050A1 (https=)
UY (1) UY39083A (https=)
WO (1) WO2021163504A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7628966B2 (ja) 2019-06-04 2025-02-12 ジエンス ヘンルイ メデイシンカンパニー リミテッド 胸線間質性リンパ球増殖因子に結合可能な抗体およびその使用
CN116601295A (zh) * 2020-12-03 2023-08-15 江苏恒瑞医药股份有限公司 一种抗tslp抗体药物组合物及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2025082377A1 (zh) * 2023-10-17 2025-04-24 江苏恒瑞医药股份有限公司 一种抗tslp抗体的药物组合物及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
ES2784123T3 (es) 2009-11-04 2020-09-22 Merck Sharp & Dohme Anticuerpo anti TSLP genomodificado
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
WO2016065181A1 (en) * 2014-10-23 2016-04-28 Amgen Inc. Reducing viscosity of pharmaceutical formulations
KR20170123315A (ko) 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
SG10202012778YA (en) * 2015-12-18 2021-01-28 Astellas Pharma Inc Pharmaceutical composition comprising anti-human tslp receptor antibody
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
EP3615065A1 (en) * 2017-04-28 2020-03-04 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
CN109952093B (zh) * 2017-07-27 2022-02-08 江苏恒瑞医药股份有限公司 一种sost抗体药物组合物及其用途
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
EP4321870B1 (en) 2018-03-13 2025-07-30 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
TW202541859A (zh) 2018-10-15 2025-11-01 美商安進公司 具有阻尼機構之藥物遞送裝置及自動注射器
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
IL293563A (en) * 2019-12-05 2022-08-01 Sanofi Aventis Us Llc Formulations of anti-cd38 antibodies for subcutaneous administration

Similar Documents

Publication Publication Date Title
JP2023513312A5 (https=)
JP7277681B2 (ja) 抗体処方物
JP7267707B2 (ja) 高濃度抗体製剤
JP2021100929A (ja) 高純度および優れた収率の正確に折り畳まれたエタネルセプト
US20060210557A1 (en) Stabilized liquid polypeptide formulations
KR20090021298A (ko) 항-egfr 항체의 동결건조 제제
CN106474470B (zh) 一种抗il-17a抗体的组合物
JP2009526856A (ja) 抗体製剤
JP2023513833A5 (https=)
CN104010658A (zh) 使用葡甲胺稳定的依那西普制剂
JP2019069973A (ja) pH範囲で結合性が異なる薬物動態改善のための抗TFPI抗体変異体
JP2014533700A5 (https=)
JP7842187B2 (ja) 抗体製剤
JP2023055977A (ja) 結晶性抗体製剤
JP7357540B2 (ja) 液体医薬組成物
JP2024119827A (ja) 抗il17a抗体の水性医薬組成物およびその使用
JP2023554087A5 (https=)
JP2020172526A (ja) 結晶性抗体製剤
WO2017055966A1 (en) Low viscosity antibody compositions
JP2015536932A (ja) Gm−csf中和化合物を含む凍結乾燥製剤
CN108602881A (zh) 抗-因子d抗体制剂
JP2023553561A (ja) Glp-1/glp-2デュアルアゴニストの医薬組成物
TW202426050A (zh) 穩定抗體組合物
KR20170113585A (ko) Glp-1r 항체 융합 단백질의 안정한 약제학적 용액 제형
JP2011519848A (ja) タンパク質製剤